VARIANTYX  POSTS

In short, yes! But let’s take a step back and start with what mitochondrial disease is.

This year we’re taking a survey of recent literature that’s influencing the way clinicians may approach genetic testing and treatment decisions for patients presenting with symptoms of kidney disorders now and in the future. Read on to learn with us …

A couple of months ago we received an email from Danny Miller, founder of the MEPAN Foundation. He wrote with what, on the surface, would seem to be a simple request: would we consider adding the MECR gene to our movement disorder, mitochondrial and neurology in-silico panels?

We’ve taken the approach of combining whole genome sequencing (WGS) with in-silico panel analysis for three key reasons: avoidance of amplification bias, detection of additional variant types and the ability to reanalyze the data at any time.